Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

YALE UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1701-10-09

Employees: 10K

Market Cap: -

Website: http://www.yale.edu

Clinical Trials

Treatment With Mecamylamine in Smoking and Non-smoking Alcohol Dependent Patients

Phase 2

Completed

Conditions: Alcoholism

Interventions: Drug: mecamylamine
Drug: Placebo

First Posted Date: 2006-06-21

Last Posted Date: 2019-06-04

Lead Sponsor: Yale University

Target Recruit Count: 136

Registration Number: NCT00342563

Locations: 🇺🇸
VA Connecticut Healthcare System, West Haven, Connecticut, United States

Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-morbid Alcoholism

Phase 2

Completed

Conditions: Alcoholism
Schizophrenia

Interventions: Drug: placebo
Drug: Glycine

First Posted Date: 2006-06-20

Last Posted Date: 2018-01-17

Lead Sponsor: Yale University

Target Recruit Count: 20

Registration Number: NCT00338598

Locations: 🇺🇸
VA Connecticut Healthcare System, West Haven, Connecticut, United States

Cognitive Training and Enhanced Supported Employment in Schizophrenia

Not Applicable

Completed

Conditions: Schizophrenia

Interventions: Behavioral: Computer-Based Cognitive Enhancement Training Program
Behavioral: Work Therapy Program

First Posted Date: 2006-06-20

Last Posted Date: 2020-03-30

Lead Sponsor: Yale University

Target Recruit Count: 98

Registration Number: NCT00339170

Locations: 🇺🇸
Connecticut Mental Health Center, New Haven, Connecticut, United States

A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma

Phase 2

Completed

Conditions: Peripheral T-Cell Lymphoma

First Posted Date: 2006-06-20

Last Posted Date: 2015-02-27

Lead Sponsor: Yale University

Target Recruit Count: 49

Registration Number: NCT00337987

Locations: 🇺🇸
Yale Comprehensive Cancer Center at Yale University School of Medicine, New Haven, Connecticut, United States

Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell Lymphoma

Phase 1

Completed

Conditions: B-Cell Lymphoma

Interventions: Drug: Clofarabine

First Posted Date: 2006-06-20

Last Posted Date: 2015-01-29

Lead Sponsor: Yale University

Target Recruit Count: 16

Registration Number: NCT00338494

Locations: 🇺🇸
Yale Comprehensive Cancer Center at Yale University School of Medicine, New Haven, Connecticut, United States

Naltrexone & SSRI in Alcoholics With Depression/PTSD

Phase 3

Completed

Conditions: Alcoholism
Depression
PTSD

Interventions: Drug: paroxetine
Drug: desipramine
Drug: Placebo
Drug: Naltrexone

First Posted Date: 2006-06-20

Last Posted Date: 2016-02-05

Lead Sponsor: Yale University

Target Recruit Count: 88

Registration Number: NCT00338962

Locations: 🇺🇸
VA Connecticut Healthcare Systems, West Haven, Connecticut, United States

A Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane in Advanced Solid Cancers

Phase 1

Terminated

Conditions: Advanced Solid Cancers

Interventions: Drug: Rapamune
Drug: Abraxane

First Posted Date: 2006-06-15

Last Posted Date: 2014-01-14

Lead Sponsor: Yale University

Target Recruit Count: 23

Registration Number: NCT00337376

Locations: 🇺🇸
Yale Comprehensive Cancer Center at Yale University School of Medicine, New Haven, Connecticut, United States

Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

Phase 2

Completed

Conditions: Liver Cancer

Interventions: Biological: bevacizumab
Drug: chemotherapy
Drug: embolization therapy
Procedure: hepatic artery infusion

First Posted Date: 2006-06-12

Last Posted Date: 2021-08-13

Lead Sponsor: Yale University

Target Recruit Count: 26

Registration Number: NCT00335829

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Relational Parenting Group for Opioid-addicted Mothers

Phase 2

Completed

Conditions: Child Abuse
Substance Abuse

First Posted Date: 2006-04-27

Last Posted Date: 2020-03-31

Lead Sponsor: Yale University

Target Recruit Count: 120

Registration Number: NCT00319241

Locations: 🇺🇸
The APT Foundation, New Haven, Connecticut, United States

Nicotinic Receptor Augmentation of SSRI Antidepressants

Phase 2

Completed

Conditions: Depressive Disorder

First Posted Date: 2006-04-27

Last Posted Date: 2007-04-19

Lead Sponsor: Yale University

Target Recruit Count: 60

Registration Number: NCT00319319

Locations: 🇺🇸
Connecticut Mental Health Center, New Haven, Connecticut, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy